Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31181856 | 1.00 | CYP11B1 (0.43) | CYP11B1CYP11B2IDO1P2RX7GPBAR1 | |
| SCHEMBL9641140 | 0.80 | HSP90AA1 (0.41) | CYP11B1CYP11B2IDO1P2RX7GPBAR1 | |
| SCHEMBL699209 | 0.78 | RAB9A (0.46) | HSP90AA1LMNANOTUM | |
| SCHEMBL9641142 | 0.75 | HSP90AA1 (0.43) | CYP11B1CYP11B2IDO1P2RX7GPBAR1 | |
| SCHEMBL2010567 | 0.72 | KLKB1 (0.43) | HPGDS | |
| SCHEMBL9641864 | 0.72 | CYP11B1 (0.51) | CYP11B1CYP11B2IDO1P2RX7GPBAR1 | |
| SCHEMBL1812632 | 0.71 | CYP11B1 (0.53) | CYP11B1CYP11B2IDO1P2RX7GPBAR1 | |
| SCHEMBL9641647 | 0.71 | CYP3A4 (0.44) | CYP11B1CYP11B2IDO1P2RX7GPBAR1 | |
| SCHEMBL3143338 | 0.71 | HSP90AA1 (0.44) | CYP11B1CYP11B2IDO1P2RX7HSP90AA1 | |
| SCHEMBL3932992 | 0.70 | CYP11B1 (0.56) | CYP11B1CYP11B2IDO1P2RX7GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113321619-A | Novel dexmedetomidine hydrochloride impurity and preparation method thereof | 南京恒正药物研究院有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20190262314-A1 | READY-TO-USE DEXMEDETOMIDINE COMPOSITIONS | SLAYBACK PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-20190262314-A1 | READY-TO-USE DEXMEDETOMIDINE COMPOSITIONS | SLAYBACK PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262314-A1 | READY-TO-USE DEXMEDETOMIDINE COMPOSITIONS | OPRD1, OPRM1, DRD2 | CYP11B1 68/4885CYP11B2 78/4885IDO1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.